Successful toxicity reduction during delayed intensification in the non-high-risk arm of Malaysia-Singapore Acute Lymphoblastic Leukaemia 2010 study

In non –high-risk (non-HR) patients, the Malaysia-Singapore Acute Lymphoblastic Leukaemia 2003 (MS2003) study achieved good outcomes. However, its delayed-intensification (DI) phase, comprising repeated blocks of protocol III (2003-PIII), was toxic and caused significant treatment delays. The successor M S2010 study attempted to lower DI toxicity by replacing myelosuppressive drugs (doxorubicin, cytarabine) with vincristine and asparaginase.

Source: European Journal of Cancer - November 24, 2020 Category: Cancer & Oncology Authors: Bernice L.Z. Oh, Shawn H.R. Lee, Koon M. Foo, Kean H. Chiew, Zelia Z.L. Seeto, Zhi W. Chen, Cheryl C.C. Neoh, Germaine S.M. Liew, Jing J. Eng, Joyce C.M. Lam, Yiong H. Chan, Thuan C. Quah, Ah M. Tan, Allen E.J. Yeoh Tags: Original Research Source Type: research